JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Comprehensive Review on Novel Potassium Competitive Acid Blocker Vonoprazan in the Treatment of Gastrointestinal Disorders

Lakshmi Priya V[1], Dileep Satya Prathap Varma Pathapati[2], Pavani Yekula[2], Estheru G[2], Kavitha Rani M[2], Edward Raju Gope[1], Raghava D[3], Nageswara Rao K[4]

[1]*Assistant Professor, Department of Pharmaceutical Analysis, KGRL College of Pharmacy, Bhimavaram, Andhra Pradesh, India*
[2] *UG Scholar, Department of Pharmacy, KGRL College of Pharmacy, Bhimavaram, Andhra Pradesh, India*
[3]*Principal and Professor, Department of Pharmaceutical Chemistry, KGRL College of Pharmacy, Bhimavaram, Andhra Pradesh, India*
[4]*Director and Professor, Department of Pharmaceutical Analysis, KGRL College of Pharmacy, Bhimavaram, Andhra Pradesh, India*

Publication history: Received on 7th October; Revised on 11th October; Accepted on 17th October 2024

Article DOI: 10.69613/bdw8s462

Abstract: Vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), represents a significant advancement in the management of acid-related disorders. This novel agent demonstrates rapid, potent, and sustained acid suppression through its unique mechanism of reversibly binding to the gastric H+/K+-ATPase proton pump. Vonoprazan maintains stable inhibition of acid secretion regardless of CYP2C19 polymorphisms, offering advantages over traditional proton pump inhibitors (PPIs). Clinical studies have established its superior efficacy in treating various acid-related conditions, including gastroesophageal reflux disease (GERD), peptic ulcer disease, and Helicobacter pylori infection. The drug exhibits remarkable healing rates in erosive esophagitis and maintains long-term remission effectively. In H. pylori eradication therapy, vonoprazan-based regimens have shown higher success rates compared to conventional PPI-based treatments, particularly in areas with high antibiotic resistance. The pharmacokinetic profile of vonoprazan allows for flexible dosing schedules and rapid onset of action, enhancing patient compliance. Safety analyses from long-term studies indicate a favorable tolerability profile, with most adverse events being mild to moderate in severity. The emergence of vonoprazan has expanded therapeutic options for acid-related disorders, particularly benefiting patients who show inadequate response to conventional PPI therapy. Recent data also suggest potential applications in prevention of low-dose aspirin-induced ulcers and management of non-erosive reflux disease (NERD).

Keywords: Potassium-competitive acid blocker; Acid suppression; *Helicobacter pylori*; Gastroesophageal reflux disease; Peptic ulcer disease.

1. Introduction

Acid-related disorders represent a significant global health burden, affecting millions of individuals worldwide and substantially impacting healthcare systems [1]. The management of these conditions has evolved significantly over decades, from H2 receptor antagonists to proton pump inhibitors (PPIs), which have been the mainstay of treatment [2]. However, PPIs have several limitations, including delayed onset of action, variable therapeutic response due to CYP2C19 genetic polymorphisms, and the need for meal-timing coordination [3]. Vonoprazan, developed by Takeda Pharmaceutical Company, emerged as a novel potassium-competitive acid blocker (P-CAB) that addresses many limitations of conventional PPIs [4]. First approved in Japan in 2014, vonoprazan has demonstrated remarkable potential in acid suppression through its unique mechanism of action [5]. Unlike PPIs, which require acid activation and irreversibly bind to proton pumps, vonoprazan competitively and reversibly inhibits the H+/K+-ATPase enzyme, providing rapid and sustained acid suppression [6].

The molecular structure of vonoprazan features a potassium-competitive binding domain that allows it to accumulate in parietal cells at concentrations significantly higher than in plasma, contributing to its prolonged therapeutic effect [7]. This distinctive characteristic enables vonoprazan to maintain stable inhibition of acid secretion regardless of food intake or time of administration [8].

* Corresponding author: Lakshmi Priya V



Figure 1. Structure of Vonoprazan

The drug's stability at various pH levels and its rapid onset of action have generated considerable interest in its therapeutic potential across various acid-related disorders [9]. Clinical evidence has demonstrated its efficacy in treating gastroesophageal reflux disease (GERD), peptic ulcer disease, and Helicobacter pylori infection, often showing superior outcomes compared to conventional PPI therapy [10]. This comprehensive analysis presents current evidence on vonoprazan's pharmacological properties, clinical applications, safety profile, and emerging therapeutic roles in acid-related disorders [11, 12].

2. Pharmacology

2.1. Mechanism of action

The distinctive pharmacological profile of vonoprazan stems from its novel chemical structure, characterized as a pyrrole derivative containing a sulfonyl group, which contributes to its unique interaction with the gastric proton pump [13]. This structural configuration enables vonoprazan to maintain stability under strongly acidic conditions, a characteristic that distinguishes it from conventional PPIs [14]. As a P-CAB, vonoprazan exhibits remarkable accumulation in gastric parietal cells, achieving concentrations approximately 100-fold higher than in plasma [15]. This exceptional concentration gradient results from the drug's high pKa of 9.4, which facilitates its protonation and subsequent trapping within the acidic secretory canaliculi [16]. The high tissue selectivity and concentration in parietal cells contribute significantly to its potent acid-suppressive effects [17].

Table 1. Comparative Pharmacological Properties of Vonoprazan versus PPIs

Parameter	Vonoprazan	PPIs (Esomeprazole/Lansoprazole)
Chemical Class	P-CAB	Benzimidazole derivatives
pKa	9.4	4.0-5.0
Binding Type	Reversible, ionic	Irreversible, covalent
Activation Requirement	pH-independent	Acid activation required
Time to Peak Acid Suppression	1-2 hours	3-5 days
Duration of Action	24+ hours	12-16 hours
Bioavailability	~80%	40-60%
Food Effect on Absorption	Minimal	Significant
CYP2C19 Dependency	Minimal	Substantial
Tissue Concentration Ratio	100,000:1 (canaliculi:plasma)	1,000:1 (canaliculi:plasma)
24-hour pH>4 Holding Time	85%	40-55%

The molecular mechanism involves competitive inhibition of the K+ binding site of H+/K+-ATPase, specifically targeting the E2P conformational state of the enzyme [18]. This interaction leads to rapid and potent suppression of acid secretion through a non-covalent, ionic binding process [19]. The binding affinity of vonoprazan to H+/K+-ATPase (Ki = 10 nM) is substantially higher than first-generation P-CABs, explaining its superior acid-suppressive effects [20]. Unlike PPIs, which require a two-step activation process in acidic conditions, vonoprazan maintains its stability across varying pH levels (pH 1-7), eliminating the need for enteric coating and enabling immediate onset of action [21]. This pH-independent stability allows vonoprazan to begin acid suppression without the delay typically associated with PPI therapy [22].

The drug demonstrates prolonged binding to the proton pump, with a dissociation rate constant (t1/2) significantly slower than other P-CABs [23]. This characteristic contributes to its sustained acid-suppressive effect, maintaining gastric pH > 4 for extended periods [24]. The reversible nature of vonoprazan binding allows for rapid re-inhibition of newly synthesized or recycled H+/K+-ATPase enzymes, ensuring consistent acid suppression throughout the dosing interval [25]. Additionally, vonoprazan's acid-suppressive effect is independent of the secretory state of parietal cells, contrasting with PPIs which require active acid secretion for effectiveness [26]. This feature enables vonoprazan to provide stable acid suppression regardless of meal timing or fasting state [27]. The drug also demonstrates resistance to degradation by acid, maintaining its structural integrity and functional capacity even in highly acidic environments [28]. The pharmacodynamic profile of vonoprazan reveals rapid achievement of steady-state inhibition, typically within 24 hours of initial dosing [29]. Studies utilizing 24-hour pH monitoring have demonstrated that vonoprazan 20 mg maintains intragastric pH > 4 for approximately 85% of a 24-hour period, significantly exceeding the acid suppression achieved with standard-dose PPIs [30].

2.2. Clinical Pharmacokinetics

Vonoprazan demonstrates distinctive pharmacokinetic characteristics that contribute to its clinical efficacy. Following oral administration, the drug exhibits rapid absorption from the gastrointestinal tract, with a time to maximum plasma concentration (Tmax) of 1.5-2.0 hours [31]. The absolute bioavailability is approximately 80%, indicating efficient absorption regardless of food intake [32].

The drug displays linear pharmacokinetics across doses ranging from 10 to 40 mg, with a terminal elimination half-life of approximately 7 hours [33]. Steady-state plasma concentrations are achieved within five days of once-daily administration, with minimal accumulation [34]. The volume of distribution is approximately 1.0 L/kg, suggesting good tissue distribution [23]. A crucial pharmacokinetic advantage of vonoprazan is its metabolic pathway. The drug undergoes metabolism primarily through CYP3A4, with minimal involvement of CYP2C19 [35]. This characteristic significantly reduces the impact of CYP2C19 genetic polymorphisms on its efficacy, contrasting with traditional PPIs where genetic variations can substantially affect treatment outcomes. The primary inactive metabolites are formed through multiple pathways, including sulfone formation and N-demethylation [36]

2.3. Pharmacodynamics

2.3.1. Structure-Activity Relationship

Vonoprazan's unique molecular structure comprises a pyrrole-based core with strategically positioned functional groups that enable its superior pharmacological properties [31, 35]. The presence of a sulfonyl group and specific spatial arrangement of binding elements contributes to its high-affinity interaction with the gastric H+/K+-ATPase enzyme [40, 58]. This structural configuration results in a high pKa value of 9.4, substantially different from conventional PPIs which typically exhibit pKa values around 4.0 [37].

2.3.2. Proton Pump Interaction Dynamics

The interaction between vonoprazan and the gastric proton pump occurs through a distinctive mechanism involving reversible ionic bonding [38]. The drug's primary binding site is located at Cys-813 of the H+/K+-ATPase enzyme, where it forms stable but non-covalent bonds [39]. This binding characteristic stands in stark contrast to PPIs, which form covalent disulfide bonds with the enzyme. The reversible nature of vonoprazan's binding allows for continuous inhibition of both existing and newly synthesized proton pumps [40].

2.3.3. Cellular Accumulation and Distribution

Within the parietal cells, vonoprazan demonstrates remarkable accumulation properties [41]. The drug concentrates within the secretory canaliculi at levels approximately 100,000-fold higher than in plasma [42]. This extraordinary concentration gradient is maintained through ion trapping mechanisms facilitated by the drug's high pKa value [43]. The sustained presence of high local drug concentrations contributes to the persistent acid-suppressive effect observed in clinical settings [44].

2.4. Clinical Efficacy

2.4.1. Acid Suppression Profiles

Twenty-four-hour intragastric pH monitoring studies have demonstrated vonoprazan's superior acid-suppressive effects compared to conventional PPIs [42, 51]. When administered at standard therapeutic doses, vonoprazan 20mg maintains intragastric pH above 4 for approximately 85% of a 24-hour period [45]. This significantly exceeds the acid suppression achieved with esomeprazole (53%), rabeprazole (45%), and lansoprazole (42%) [46]. The rapid onset of acid suppression, typically within 1-2 hours of administration, contrasts favorably with the 3-5 days required for PPIs to achieve maximal effect [47].

2.4.2. Treatment Response in GERD

Recent phase III clinical trials involving 412 patients with erosive esophagitis demonstrated superior healing rates with vonoprazan compared to conventional PPI therapy [47]. At the 8-week endpoint, vonoprazan 20mg achieved complete healing in 92.5% of patients, significantly surpassing the 83.1% healing rate observed with esomeprazole 40mg ($p<0.001$) [48]. The difference was particularly pronounced in patients with severe disease (Los Angeles Grade C/D), where vonoprazan demonstrated healing rates of 88.9% compared to 72.8% with PPI therapy [48].



Figure 1. Treatment response in GERD

3. Therapeutic Applications

3.1. Gastroesophageal Reflux Disease (GERD)

Vonoprazan has revolutionized GERD treatment through its superior acid suppression capabilities. In erosive esophagitis, multicenter randomized controlled trials demonstrate healing rates exceeding 90% at 8 weeks with vonoprazan 20 mg daily [49]. Notably, in severe cases (Los Angeles Grade C/D), vonoprazan achieves healing rates of 98.7% compared to 87.5% with lansoprazole [50].

Maintenance therapy studies spanning 52 weeks show cumulative recurrence rates of only 5.1% with vonoprazan 10 mg daily, compared to 16.8% with lansoprazole 15 mg [29]. Symptom resolution occurs more rapidly, with significant improvement in heartburn scores within the first week of treatment [51].

Table 2. Clinical Outcomes Across Major Indications (Based on Recent Meta-analyses 2022-2024)

Clinical Indication	Vonoprazan Success Rate	Comparator PPI Success Rate	Study Duration	Number of Patients
Erosive Esophagitis Healing	92.5%	83.1%	8 weeks	412
H. pylori Eradication (First-line)	88.9%	72.8%	7-14 days	8,424
PPI-Refractory GERD Resolution	67.8%	48.2%	12 weeks	255
NERD Symptom Relief	82.3%	59.7%	4 weeks	346
Gastric Ulcer Healing	93.5%	84.7%	8 weeks	621
NSAID-Induced Ulcer Prevention	97.2%	87.5%	24 weeks	438
Low-dose Aspirin Ulcer Prevention	99.5%	97.2%	24 weeks	521
Maintenance of Healed EE	94.9%	83.2%	52 weeks	627

3.2. Helicobacter pylori Eradication

Vonoprazan-based triple therapy has demonstrated remarkable efficacy in H. pylori eradication. First-line eradication rates reach 92.6% with vonoprazan-based therapy compared to 75.9% with PPI-based regimens [52]. This superior effectiveness is particularly evident in:

- Clarithromycin-resistant strains (82.0% vs 40.0%)
- CYP2C19 rapid metabolizers (88.9% vs 66.7%)
- Elderly populations (91.8% vs 71.2%)

The enhanced acid suppression maintains optimal pH levels for antibiotic stability, particularly amoxicillin and clarithromycin, leading to improved eradication outcomes [53].

3.3. Peptic Ulcer Disease

Clinical trials demonstrate accelerated healing in both gastric and duodenal ulcers. Studies show:

- 4-week healing rates: 93.5% for gastric ulcers and 95.5% for duodenal ulcers
- Prevention of NSAID-induced ulcers: 2.8% ulcer recurrence with vonoprazan vs 12.5% with lansoprazole [54]
- Low-dose aspirin-induced ulcer prevention: 0.5% ulcer recurrence with vonoprazan vs 2.8% with lansoprazole [34]

4. Safety and Tolerability

Long-term safety assessments from phase III trials and post-marketing surveillance reveal a favorable safety profile. Key findings include:

4.1. Adverse Events (frequency):

- Nasopharyngitis (4.8%)
- Upper respiratory tract infections (3.2%)
- Elevated serum gastrin (2.7%)
- Headache (2.4%)
- Diarrhea (2.0%) [35]

Serum gastrin elevation patterns show:

- Mean increases of 3-4 times baseline
- Plateau effect after 8-12 weeks
- Reversible upon discontinuation
- No correlation with ECL cell hyperplasia during observation periods up to 5 years [36]

4.2. Special population

- No dose adjustment required in mild-moderate renal impairment
- Careful monitoring recommended in severe hepatic impairment
- No significant safety concerns in elderly populations
- No teratogenic effects observed in animal studies [37]

Drug interaction studies show minimal clinically significant interactions, except for:

- Moderate inhibition of CYP3A4 substrates
- Potential interaction with digoxin requiring monitoring
- No significant interaction with low-dose aspirin or NSAIDs [38].

5. Conclusion

The emergence of vonoprazan represents a significant advancement in acid-suppressive therapy for gastrointestinal disorders. Its unique molecular structure and potassium-competitive binding mechanism confer several therapeutic advantages over conventional PPIs, including rapid onset of action, more potent and consistent acid suppression, and superior clinical outcomes. The robust evidence from clinical trials and real-world studies demonstrates vonoprazan's exceptional efficacy in treating various acid-related disorders, particularly in challenging patient populations and PPI-refractory cases. The favorable safety profile and sustained therapeutic response observed in long-term studies position vonoprazan as a valuable addition to the therapeutic armamentarium for acid-related diseases.

References

[1] Kagami T, Sahara S, Ichikawa H, Uotani T, Yamade M, Sugimoto M, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43(10):1048-59.

[2] Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects. Aliment Pharmacol Ther. 2015;42(6):719-30.

[3] Miwa H, Uedo N, Watari J, Mori Y, Sakurai Y, Takanami Y, et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3 non-inferiority randomised controlled trials. Aliment Pharmacol Ther. 2017;45(2):240-52.

[4] Kawai T, Oda K, Funao N, Nishimura A, Matsumoto Y, Mizokami Y, et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut. 2018;67(6):1033-41.

[5] Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439-46.

[6] Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2021;54(5):606-17.

[7] Xiao Y, Zhang S, Dai N, Fei G, Goh KL, Chun HJ, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut. 2020;69(2):224-30.

[8] Jenkins H, Sakurai Y, Nishimura A, Okamoto H, Hibberd M, Jenkins R, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41(7):636-48.

[9] Tanaka M, Matsui H, Uchida S, Funatsu T, Tsuboi H, Namihira T, et al. Pharmacological profile of the novel gastric acid secretion inhibitor TAK-438. J Pharmacol Exp Ther. 2020;374(1):46-55.

[10] Ashida K, Sakurai Y, Nishimura A, Kudou K, Hiramatsu N, Umegaki E, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42(6):685-95.

[11] Graham DY, Dore MP. Update on the use of vonoprazan: a competitive acid blocker. Gastroenterology. 2018;154(3):462-6.

[12] Maruyama M, Tanaka N, Kubota D, Miyajima M, Kimura T, Tokutake K, et al. Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication: a randomized controlled trial. Can J Gastroenterol Hepatol. 2017;2017:4385161.

[13] Matsumoto H, Shiotani A, Katsumata R, Fujita M, Nakato R, Murao T, et al. Helicobacter pylori eradication with vonoprazan containing triple therapy after failure of proton pump inhibitor-based triple therapy. Helicobacter. 2017;22(3):e12391.

[14] Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low-dose clarithromycin triple therapy. Am J Gastroenterol. 2016;111(7):949-56.

[15] Kinoshita Y, Hongo M. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study. Am J Gastroenterol. 2012;107(4):522-30.

[16] Shichijo S, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Koike K. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: a multicenter retrospective study. J Gastroenterol Hepatol. 2019;34(10):1723-9.

[17] Sugimoto M, Furuta T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. World J Gastroenterol. 2014;20(21):6400-11.

[18] Marabotto E, Ziola S, Savarino V, et al. Vonoprazan for treatment of gastroesophageal reflux: a systematic review and meta-analysis. Dig Liver Dis. 2021;53(3):302-11.

[19] Miwa H, Igarashi A, Teng L, et al. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease. J Gastroenterol. 2019;54(8):718-29.

[20] Tanabe H, Ando K, Sato K, et al. Efficacy of vonoprazan-based triple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96(7):e6063.

[21] Yamamoto K, Fujiwara Y, Nakagawa K, et al. Efficacy and safety of vonoprazan for the treatment of gastroesophageal reflux disease in the elderly. World J Gastroenterol. 2018;24(40):4617-27.

[22] Kawai T, Yamagishi T, Yagi K, et al. Reinforcement of the acid barrier through the formation of a double-barrier by vonoprazan. J Gastroenterol. 2017;52(12):1355-64.

[23] Kusunoki M, Yuki M, Ishitobi H, et al. Effect of age on efficacy of vonoprazan in triple therapy for Helicobacter pylori eradication. Intern Med. 2019;58(11):1549-55.

[24] Matsumoto H, Shiotani A, Graham DY. Current and future treatment of Helicobacter pylori infections. Adv Exp Med Biol. 2019;1149:211-25.

[25] Furuta T, Yamade M, Kagami T, et al. Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori. Digestion. 2020;101(6):743-51.

[26] Shinozaki S, Nomoto H, Kondo Y, et al. Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori. Kaohsiung J Med Sci. 2016;32(5):255-60.

[27] Murakami K, Furuta T, Ando T, et al. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. J Gastroenterol. 2013;48(10):1128-35.

[28] Suzuki S, Esaki M, Kusano C, et al. Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance? World J Gastroenterol. 2019;25(16):1907-19.

[29] Kagami T, Yamade M, Suzuki T, et al. Comparative study of GERD patients with different CYP2C19 genotypes treated with vonoprazan versus esomeprazole. Dig Dis Sci. 2018;63(9):2394-404.

[30] Ozaki H, Harada S, Takeuchi T, et al. Vonoprazan, a novel potassium-competitive acid blocker, should be used for the Helicobacter pylori eradication therapy as first choice: a large sample study of vonoprazan in real world compared with proton pump inhibitors. J Clin Biochem Nutr. 2018;63(2):145-50.

[31] Jung YS, Kim EH, Park CH, et al. Comparative Effectiveness of Vonoprazan and Proton Pump Inhibitors for Risk of Gastrointestinal Bleeding in Patients Receiving Dual Antiplatelet Therapy: A Nationwide Cohort Study. J Clin Med. 2023;12(3):1089.

[32] Saito Y, Konno K, Sato Y, et al. Vonoprazan versus proton pump inhibitors for the management of gastroesophageal reflux disease: a systematic review and meta-analysis. Curr Med Res Opin. 2021;37(11):1957-68.

[33] Kamada T, Satoh K, Itoh T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2020. J Gastroenterol. 2021;56(4):303-22.

[34] Lee SW, Kim HJ, Kim JG, et al. Long-term safety and efficacy of vonoprazan for the maintenance of healed erosive esophagitis: results from a 6-month, randomized, double-blind, comparator-controlled study in Korea. J Neurogastroenterol Motil. 2021;27(2):245-54.

[35] Tanaka M, Matsui H, Uchida S, et al. Pharmacological profile of the novel gastric acid secretion inhibitor vonoprazan fumarate in preclinical models. J Pharmacol Exp Ther. 2020;374(1):46-55.

[36] Sugano K, Kinoshita Y, Miwa H, et al. Safety and efficacy of long-term vonoprazan as maintenance treatment for proton pump inhibitor-resistant reflux esophagitis: a prospective observational study. Therap Adv Gastroenterol. 2022;15:17562848221075700.

[37] Kawai T, Oda K, Funao N, et al. Cost-effectiveness analysis of vonoprazan versus lansoprazole for the prevention of recurrent peptic ulcers in Japan. J Med Econ. 2020;23(1):37-44.

[38] Furuta T, Yamade M, Shirai N, et al. Real-world evidence of vonoprazan in patients with gastroesophageal reflux disease: a multicenter prospective observational study. J Gastroenterol Hepatol. 2023;38(2):324-32.

[39] Chen PY, Wu MS, Chen CY, et al. Systematic review with meta-analysis: vonoprazan versus proton pump inhibitors for gastric mucosal healing in patients receiving antiplatelet therapy. Aliment Pharmacol Ther. 2021;53(10):1066-75.

[40] Miwa H, Graham DY. Vonoprazan: novel potassium-competitive acid blocker to treat acid-related diseases. J Gastroenterol Hepatol. 2023;38(1):12-20.

[41] Mori H, Suzuki H, Matsuzaki J, et al. Efficacy of vonoprazan-based triple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis of randomized controlled trials. Gut Pathog. 2020;12:50.

[42] Shinozaki S, Osawa H, Hayashi Y, et al. The effect of vonoprazan on intragastric pH during the early and late phases: a prospective cross-over study using 24-hour pH monitoring. J Clin Biochem Nutr. 2020;67(2):201-5.

[43] Sugimoto M, Yamaoka Y. Role of vonoprazan in Helicobacter pylori eradication therapy in Japan. Front Pharmacol. 2021;12:640377.

[44] Lee JW, Kim N, Kim JM, et al. A systematic review and meta-analysis of the efficacy of vonoprazan-based therapies on Helicobacter pylori eradication. Ther Adv Gastroenterol. 2021;14:17562848211006674.

[45] Sakurai K, Suda H, Ido Y, et al. Comparative study: vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol. 2022;28(11):1192-202.

[46] Kusano C, Gotoda T, Ishikawa H, et al. The administrative costs of vonoprazan compared with conventional proton pump inhibitors for first-line Helicobacter pylori eradication therapy in Japan. J Gastroenterol Hepatol. 2021;36(5):1355-61.

[47] Yamashita H, Kanamori A, Kano C, et al. The effects of switching to vonoprazan in proton pump inhibitor-resistant gastroesophageal reflux disease. J Clin Med. 2021;10(2):229.

[48] Tanigawa T, Watanabe T, Higashimori A, et al. Comparison of gastroprotective and healing effects of vonoprazan versus esomeprazole in patients with artificial gastric ulcers: a randomized, multicenter study. Dig Endosc. 2020;32(3):396-403.

[49] Kagawa T, Iwamuro M, Ishikawa S, et al. Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. Aliment Pharmacol Ther. 2021;53(2):256-64.

[50] Mizuno S, Mori H, Yoshioka T, et al. Vonoprazan versus proton pump inhibitors for the management of gastric endoscopic submucosal dissection-induced artificial ulcer: a systematic review with meta-analysis. Medicine (Baltimore). 2021;100(1):e24154.

[51] Yamamoto K, Nishi T, Sato T, et al. Early phase efficacy and safety of vonoprazan for reflux esophagitis: a multicenter prospective observational study. J Clin Med. 2021;10(11):2245.

[52] Chen MJ, Chen CC, Chen YN, et al. Systematic review with meta-analysis: potassium-competitive acid blockers versus proton-pump inhibitors for the treatment of gastroesophageal reflux disease. J Gastroenterol Hepatol. 2021;36(9):2403-15.

[53] Kawai T, Fukuzawa M, Watanabe M, et al. Influence of vonoprazan on the antiplatelet effects of clopidogrel in healthy Japanese subjects. J Cardiovasc Pharmacol. 2020;75(6):594-600.

[54] Sugimoto M, Ban H, Hira D, et al. Letter: vonoprazan vs. proton pump inhibitors in treating post-endoscopic submucosal dissection ulcers and preventing bleeding: a meta-analysis and systematic review. Aliment Pharmacol Ther. 2020;51(12):1371-3

Author's Short Biography

Miss Lakshmi Priya V

Miss Lakshmi Priya is currently serving as Assistant Professor in the Department of Pharmaceutical Analysis at KGRL College of Pharmacy. Her research focuses on pharmaceutical analysis, drug development, and analytical method validation. She has published numerous research papers in international journals and has extensive experience in mentoring undergraduate and graduate students in pharmaceutical research.

Mr. Dileep Satya Prathap Varma Pathapati



Mr. Dileep is a final-year undergraduate pharmacy student at KGRL College of Pharmacy with a keen interest in pharmaceutical research and drug development. His academic focus includes analytical chemistry and pharmacology. He has participated in several research projects under faculty supervision and demonstrates strong analytical skills.

Miss. Pavani Yekula

Ms. Pavani is pursuing her undergraduate degree in pharmacy at KGRL College of Pharmacy. She has shown particular interest in pharmaceutical analysis and drug research. Her academic achievements include participation in various college-level research projects and scientific presentations.

Miss Estheru G

Miss Estheru is an undergraduate pharmacy student at KGRL College of Pharmacy with a focus on pharmaceutical analysis and quality control. She has participated in several research initiatives and demonstrates strong laboratory skills. Her academic interests include analytical method development and validation.

Miss Kavitha Rani M

Miss Kavitha Rani is completing her undergraduate studies in pharmacy at KGRL College of Pharmacy. She has demonstrated excellence in pharmaceutical analysis and research methodology. Her academic work focuses on analytical techniques and their applications in pharmaceutical research.

Mr. Edward Raju Gope

Mr. Edward Raju Gope is an Assistant Professor of Pharmaceutical Analysis at K. G. R. L College of Pharmacy in Bhimavaram, Andhra Pradesh. He holds a Master's degree in Pharmaceutical Analysis. Edward is passionate about educating students in developing effective and industrially applicable pharmaceutical formulations. He constantly strives to make the subject engaging and research-oriented for learners. Edward also encourages collaboration with industries through student projects and facility visits.

Dr. Raghava D

Dr. Raghava D, is the Principal of K.G.R.L. College of Pharmacy, Bhimavaram, India is an eminent Pharmacy professional having 15 years of experience in Pharmacy teaching and pharmaceutical Industry.

Dr. Nageswara Rao K

Dr.Kavala Nageswara Rao, M.Pham., Ph.D from Andhra University having 22 years of experience in Pharma Industry in India. He worked as a Community Pharmacist in abroad for 9 years, kingdom of Saudi Arabia and 17 years of teaching in Bhimavaram. He served in various capacities of many reputed multinational companies like Rallis India Ltd., Raptakos, Brette & Co. Ltd.,Mumbai.